Tiziana生命科学公司宣布，其鼻内福拉单抗（Foralumab）2a期Banyan临床试验的海报将在ALS Nexus 2026会议上进行展示。
该海报将呈现这项针对肌萎缩侧索硬化症（ALS）患者的临床试验数据。ALS Nexus 2026是聚焦于肌萎缩侧索硬化症研究与治疗的重要学术会议。
鼻内福拉单抗是Tiziana生命科学公司研发的一种创新性免疫调节剂，通过鼻腔给药途径递送，旨在调节免疫反应，延缓疾病进展。此次海报展示将为与会者提供关于该候选药物在2a期临床试验中的安全性、耐受性及初步疗效数据。
Tiziana生命科学公司致力于开发针对神经退行性疾病的突破性疗法，此次在海内外学术会议上亮相，也体现了其在ALS治疗领域的研究进展与决心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.